New drug approved to treat HIV. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

New drug approved to treat HIV. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Treat Rev. 1997 Apr;(No 24):5. Unique Identifier : AIDSLINE AIDS/97702572

Abstract: Nelfinavir (Viracept) was approved in March 1997 by the Food and Drug Administration (FDA) as the fourth commercially-available protease inhibitor. It, like the others, is most effective in combination with two nucleoside analogs. The major side effect is diarrhea, and in the study, most patients tolerated it well enough that few dropped out. Nelfinavir impacts liver function and the liver should be monitored when this drug is prescribed. Early studies show that resistance to nelfinavir would not compromise the effectiveness of other protease inhibitors.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Adult CD4 Lymphocyte Count/DRUG EFFECTS Child Clinical Trials Diarrhea/CHEMICALLY INDUCED *Drug Approval *Drug Interactions Drug Resistance, Microbial Drug Therapy, Combination HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS Human Isoquinolines/*ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS Sulfonic Acids/*ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS United States United States Food and Drug Administration Viral Load NEWSLETTER ARTICLE
970830
M9781179

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .